Figure 1
Bone marrow mesenchymal stem cells inhibit the growth of metastatic tumor ( n  = 14). Day 0, 2 × 105 B16-F10 tumor cells were injected via the tail vein of C57 mice. On days 0, 7, and 14, the mice received syngeneic 5 × 105 cells/mouse bone marrow mesenchymal stem cell (BMSC) treatment. C57 mice injected with B16-F10 without BMSC treatment served as the control. Thirty-five days after B16-F10 injection, five animals from each group were sacrificed and resected lungs were weighed. The survival time of the remaining mice was monitored. BALb/c mice were inoculated intraperitoneally with 5× 105 H22 tumor cells. On days 0 and 7, the mice received syngeneic 5 × 105 cells/mouse BMSC treatment. BALb/c mice injected with B16-F10 cells without BMSC treatment served as the control. Mouse body weight was calculated and the survival time of the mice was monitored continuously. (A) Example of tumor formation in a lung of the C57 mouse tumor model and BMSC-treated mouse. Less tumor was formed in the BMSC-treated mouse compared with the control group. (B) Lung weight of C57 mice. (C) Survival time of C57 mice. (D) Body weight of BALb/c mice. (E) Survival time of BALb/c mice. BMSCs, bone marrow mesenchymal stem cell-treated group; CT, control (tumor model) group.